RYTM Christopher Paul German sells $324K worth of shares
Jul 12, 2025, 4:37 AM
0.00%
What does RYTM do
Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
Christopher Paul German sold 3,817 shares of RYTM on 9 July at $85.00 per share, worth a total of $324K. They now own 2,772 RYTM shares, or a 81% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
